Research progress of metformin in gestational diabetes mellitus: a narrative review
Abstract
Gestational diabetes mellitus (GDM) refers to abnormal glucose metabolism that occurs during pregnancy, where blood glucose does not reach the level of overt diabetes during pregnancy. Poor blood glucose control in GDM patients can pose a serious threat to pregnant women and their fetuses by giving rise to adverse pregnancy outcomes for mothers and infants. In 2015, the International Federation of Gynecology and Obstetrics (FIGO) recommended that insulin and metformin be used as the first-line medications for patients with GDM who did not reach the ideal blood glucose level following lifestyle interventions. Recent research has also highlighted the clinical value of metformin with its application for polycystic ovary syndrome (PCOS) treatment, reducing GDM and gestational hypertension syndrome risk along with miscarriage rate in early pregnancy; however, there is no clear consensus regarding the efficacy of metformin treatment in pregnant women with GDM pertaining to its effects on fetal malformation, long-term growth and development of offspring, blood glucose in pregnant women, and maternal and infant outcomes. Therefore, to further understand the safety and efficacy of metformin in the treatment of GDM will provide theoretical basis for the choice of reasonable drugs and the observation the disease trends and outcomes. This review summarizes the most recent literature on safety and efficacy of metformin treatment in GDM. Meanwhile, the effect of metformin on the incidence…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.